Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 6/2010

Open Access 01-06-2010 | Original Article

Cost-Effectiveness of Strategies to Improve HIV Testing and Receipt of Results: Economic Analysis of a Randomized Controlled Trial

Authors: Gillian D. Sanders, PhD, Henry D. Anaya, PhD, Steven Asch, MD, MPH, Tuyen Hoang, PhD, Joya F. Golden, MSW, Ahmed M. Bayoumi, MD, MSc, Douglas K. Owens, MD, MS

Published in: Journal of General Internal Medicine | Issue 6/2010

Login to get access

Abstract

Background

The CDC recommends routine voluntary HIV testing of all patients 13-64 years of age. Despite this recommendation, HIV testing rates are low even among those at identifiable risk, and many patients do not return to receive their results.

Objective

To examine the costs and benefits of strategies to improve HIV testing and receipt of results.

Design

Cost-effectiveness analysis based on a Markov model. Acceptance of testing, return rates, and related costs were derived from a randomized trial of 251 patients; long-term costs and health outcomes were derived from the literature.

Setting/target population

Primary-care patients with unknown HIV status.

Interventions

Comparison of three intervention models for HIV counseling and testing: Model A = traditional HIV counseling and testing; Model B = nurse-initiated routine screening with traditional HIV testing and counseling; Model C = nurse-initiated routine screening with rapid HIV testing and streamlined counseling.

Main measures

Life-years, quality-adjusted life-years (QALYs), costs and incremental cost-effectiveness.

Key results

Without consideration of the benefit from reduced HIV transmission, Model A resulted in per-patient lifetime discounted costs of $48,650 and benefits of 16.271 QALYs. Model B increased lifetime costs by $53 and benefits by 0.0013 QALYs (corresponding to 0.48 quality-adjusted life days). Model C cost $66 more than Model A with an increase of 0.0018 QALYs (0.66 quality-adjusted life days) and an incremental cost-effectiveness of $36,390/QALY. When we included the benefit from reduced HIV transmission, Model C cost $10,660/QALY relative to Model A. The cost-effectiveness of Model C was robust in sensitivity analyses.

Conclusions

In a primary-care population, nurse-initiated routine screening with rapid HIV testing and streamlined counseling increased rates of testing and receipt of test results and was cost-effective compared with traditional HIV testing strategies.
Appendix
Available only for authorised users
Literature
1.
Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–7. quiz CE1-4.PubMed
2.
Wortley PM, Chu SY, Diaz T, et al. HIV testing patterns: where, why, and when were persons with AIDS tested for HIV? Aids. 1995;9(5):487–92.PubMed
3.
Late HIV testing—34 states, 1996-2005. MMWR Morb Mortal Wkly Rep. 2009;58(24):661-5.
4.
HIV prevalence estimates—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(39):1073-6.
5.
Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2009.
6.
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. Aids. 2006;20(10):1447–50.CrossRefPubMed
7.
Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic—United States, 2003. MMWR. 2003;52(15):329–32.
8.
Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. Jama. 2008;300(5):520–9.CrossRefPubMed
9.
Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150(2):125–31.PubMed
10.
Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797–806.PubMed
11.
Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States–an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.CrossRefPubMed
12.
Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.CrossRefPubMed
13.
Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889–903.PubMed
14.
Owens DK, Sundaram V, Lazzeroni LC, et al. HIV testing of at risk patients in a large integrated health care system. J Gen Intern Med. 2007;22(3):315–20.CrossRefPubMed
15.
Tao G, Branson BM, Kassler WJ, Cohen RA. Rates of receiving HIV test results: data from the U.S. National Health Interview Survey for 1994 and 1995. J Acquir Immune Defic Syndr. 1999;22(4):395–400.PubMed
16.
Hutchinson AB, Branson BM, Kim A, Farnham PG. A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status. Aids. 2006;20(12):1597–604.CrossRefPubMed
17.
Anaya HD, Hoang T, Golden JF, et al. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med. 2008;23(6):800–7.CrossRefPubMed
18.
Gold MR, Seigel JE, Russell LB, Weinstein MC (eds). Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
19.
Garber AM. Recent developments in CBA/CEA. In: Culver AJ, Newhouse JP (eds) Handbook of health economics. 1 ed: Elsevier Science B.V; 2000.
20.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Jama. 1996;276(15):1253–8.CrossRefPubMed
21.
22.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–38.CrossRefPubMed
23.
Koblin BA, van Benthem BH, Buchbinder SP, et al. Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995. Am J Epidemiol. 1999;150(10):1026–30.PubMed
24.
Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370(9603):1923–8.CrossRefPubMed
25.
King JT Jr, Justice AC, Roberts MS, Chang CC, Fusco JS. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making. 2003;23(1):9–20.CrossRefPubMed
26.
Rosenberg PS. Scope of the AIDS epidemic in the United States. [see comments]. Science. 1995;270(5240):1372–5.CrossRefPubMed
27.
Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health. 2001;91(7):1060–8.CrossRefPubMed
28.
Karon JM, Song R, Brookmeyer R, Kaplan EH, Hall HI. Estimating HIV incidence in the United States from HIV/AIDS surveillance data and biomarker HIV test results. Stat Med. 2008;27(23):4617–33.CrossRefPubMed
29.
Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89–102.CrossRefPubMed
30.
Executive Office of the President of the United States. Budget of the United States Government, Fiscal Year 2009: Historical tables in spreadsheet format. Section 10: 10.1— Gross Domestic Product and Deflators Used in the Historical Tables: 1940-2013 Gross Domestic Product and Implicit Outlay Deflators. Vol. 2008; 2008.
31.
Atri J, Falshaw M, Gregg R, Robson J, Omar RZ, Dixon S. Improving uptake of breast screening in multiethnic populations: a randomised controlled trial using practice reception staff to contact non-attenders. Bmj. 1997;315(7119):1356–9.PubMed
32.
Cargill VA, Conti M, Neuhauser D, McClish D. Improving the effectiveness of screening for colorectal cancer by involving nurse clinicians. Med Care. 1991;29(1):1–5.CrossRefPubMed
33.
34.
Gonzalez JJ, Ranney J, West J. Nurse-initiated health promotion prompting system in an internal medicine residents' clinic. South Med J. 1989;82(3):342–4.PubMed
35.
Robson J, Boomla K, Fitzpatrick S, et al. Using nurses for preventive activities with computer assisted follow-up: a randomised controlled trial. Bmj. 1989;298(6671):433–6.CrossRefPubMed
36.
Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med. 2002;136(9):641–51.PubMed
37.
Metcalf CA, Douglas JM Jr, Malotte CK, et al. Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):130–8.CrossRefPubMed
38.
Lyss SB, Branson BM, Kroc KA, Couture EF, Newman DR, Weinstein RA. Detecting unsuspected HIV infection with a rapid whole-blood HIV test in an urban emergency department. J Acquir Immune Defic Syndr. 2007;44(4):435–42.CrossRefPubMed
39.
Rapid HIV testing in outreach and other community settings—United States, 2004-2006. MMWR Morb Mortal Wkly Rep. 2007;56(47):1233–7.
40.
Kassler WJ, Dillon BA, Haley C, Jones WK, Goldman A. On-site, rapid HIV testing with same-day results and counseling. Aids. 1997;11(8):1045–51.CrossRefPubMed
41.
Kroc K, Kendrick S, Withum D et al. Rapid HIV Testing in an Emergency Department. Vol. 2008; 2002.
42.
Haukoos JS, Hopkins E, Byyny RL. Patient acceptance of rapid HIV testing practices in an urban emergency department: assessment of the 2006 CDC recommendations for HIV screening in health care settings. Ann Emerg Med. 2008;51(3):303–9. 309 e1; discussion 310-1.CrossRefPubMed
43.
Silva A, Glick NR, Lyss SB, et al. Implementing an HIV and sexually transmitted disease screening program in an emergency department. Ann Emerg Med. 2007;49(5):564–72.CrossRefPubMed
44.
Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 2008;123(Suppl 3):51–62.PubMed
45.
Mehta SD, Hall J, Greenwald JL, Cranston K, Skolnik PR. Patient risks, outcomes, and costs of voluntary HIV testing at five testing sites within a medical center. Public Health Rep. 2008;123(5):608–17.PubMed
46.
Walensky RP, Arbelaez C, Reichmann WM, et al. Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med. 2008;149(3):153–60.PubMed
47.
Walensky RP, Arbelaez CA, Reichmann WM, Walls RM, Katz JN, Losina E. Revisiting Expectations from Rapid HIV Test and Confirmation in the Emergency Department [Abstract]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008.
48.
Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006;8(2):125–31.CrossRefPubMed
49.
Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. Jama. 2004;292(2):251–65.CrossRefPubMed
50.
Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Vol. 2008: Department of Health and Human Services; 2008.
Metadata
Title
Cost-Effectiveness of Strategies to Improve HIV Testing and Receipt of Results: Economic Analysis of a Randomized Controlled Trial
Authors
Gillian D. Sanders, PhD
Henry D. Anaya, PhD
Steven Asch, MD, MPH
Tuyen Hoang, PhD
Joya F. Golden, MSW
Ahmed M. Bayoumi, MD, MSc
Douglas K. Owens, MD, MS
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2010
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1265-5

Other articles of this Issue 6/2010

Journal of General Internal Medicine 6/2010 Go to the issue

Clinical Review

Good Neighbors: How Will the Patient-Centered Medical Home Relate to the Rest of the Health-Care Delivery System?

Editorial

Using Evidence to Inform Policy: Developing a Policy-Relevant Research Agenda for the Patient-Centered Medical Home

Review

How to Buy a Medical Home? Policy Options and Practical Questions

Original Article

Validation of the Group-Based Medical Mistrust Scale Among Urban Black Men

Perspectives

How to Scale Up Primary Care Transformation: What We Know and What We Need to Know?

Original Article

Electronic Prescribing Improves Medication Safety in Community-Based Office Practices
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits